PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5140275

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE AND REASSIGNMENT OF SECURITY INTEREST RECORDED AT REEL/FRAME 44275/0032	

CONVEYING PARTY DATA

Name	Execution Date
NXT CAPITAL, LLC	08/02/2018

RECEIVING PARTY DATA

Name:	GLEN RESEARCH, LLC		
Street Address:	22825 DAVIS DRIVE		
City:	STERLING		
State/Country:	VIRGINIA		
Postal Code:	20164		

PROPERTY NUMBERS Total: 4

Property Type	Number
Patent Number:	6770754
Patent Number:	7491817
Patent Number:	8394948
Patent Number:	7144995

CORRESPONDENCE DATA

Fax Number: (312)862-2200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128622000

Email: rob.soneson@kirkland.com

Correspondent Name: ROB SONESON Address Line 1: 300 N LASALLE

Address Line 2: KIRKLAND & ELLIS LLP Address Line 4: CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER:	17585-1-RFS
NAME OF SUBMITTER:	ROB SONESON
SIGNATURE:	/rsoneson/
DATE SIGNED:	09/13/2018

Total Attachments: 3

source=nxt vector patent release (glen research) (executed)#page1.tif

PATENT REEL: 047073 FRAME: 0116

505093515

source=nxt vector patent release (glen research) (executed)#page2.tif source=nxt vector patent release (glen research) (executed)#page3.tif

PATENT REEL: 047073 FRAME: 0117

PATENT RELEASE AND REASSIGNMENT

THIS PATENT RELEASE AND REASSIGNMENT is made as of August 2, 2018, by NXT CAPITAL, LLC, as administrative agent ("Agent"). Capitalized terms used but not defined herein shall have the same meanings assigned to such terms in the Security Agreement (as defined below).

WITNESSETH:

WHEREAS, Glen Research, LLC, a Delaware limited liability company ("<u>Grantor</u>") and Agent are parties to a Patent Security Agreement dated as of December 1, 2017 (the "<u>Security Agreement</u>"), pursuant to which Grantor granted a security interest to Agent for the benefit of the Secured Parties, in the Patent Collateral as security for certain obligations owing by Grantor to the Secured Parties including certain patents (the "<u>Patents</u>") set forth on <u>Schedule A</u> hereto; and

WHEREAS, the Security Agreement was recorded by the United States Trademark and Patent Office on December 1, 2017 at Reel 44275, Frame 0032; and

WHEREAS, Grantor has requested that Agent release its security interest in the Patents and Patent Collateral and reassign the same to the Grantor.

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

- 1. Agent hereby terminates, discharges and releases all of its security interest in all of Grantor's right, title and interest in and to the Patent Collateral, including the Patents set forth on <u>Schedule A</u>, and hereby terminates the Security Agreement.
- 2. Agent hereby reassigns, grants and conveys to Grantor, without any representation, recourse, warranty or undertaking by Agent, all of Agent's right, title and interest in and to the Patent Collateral and the Patents.
- 3. Agent agrees to take all further actions, and provide to Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by Grantor, at Grantor's sole cost and expense, to more fully and effectively effectuate the purposes hereunder.
 - Remainder of Page Intentionally Left Blank; Signature Page Follows -

US_134697311v2

PATENT REEL: 047073 FRAME: 0118 IN WITNESS WHEREOF, Agent has caused this Patent Release and Reassignment to be executed as of the day and year first above written.

NXT CAPITAL, LLC, as Agent

By: Brian Schleich

Title: Director

SCHEDULE A

PATENTS

App No.	Filing Date	Country	<u>Title</u>	Pat. No.	Issue Date
01998648	11/29/2001	EP	Universal Supports for oligonucleotide synthesis	1404695	4/10/2013
01998648	11/29/2001	EP	Universal supports for oligonucleotide synthesis	2248820	1/8/2014
10168076	11/29/2001	US	Universal supports for oligonucleotide synthesis	6,770,754	8/3/2004
09/995,785	5/24/2004	US	Universal supports for oligonucleotide synthesis	7,491,817	2/17/2009
10/851,289	9/28/2010	US	Reagents utilizing a serinol scaffold for labeling synthetic oligonucleotide ¹	8,394,948	3/12/2013
12/891,888	3/6/2003	US	Fluorescent nitrogenous base and nucleosides incorporating same ²	7,144,995	12/5/2006
10/382,754	3/6/2003	EP	Fluorescent Nitrogenous Base and Nuclosides Incorporating Same	1483280	10/24/2012

PATENT REEL: 047073 FRAME: 0120

Joint patent with Nelson Biotechnologies, Inc.

 $[\]frac{2}{2}$ Joint patent with Berry & Associates.